iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

JB Chemicals & Pharma: 70-75% of incremental Cap allocation towards India

21 Mar 2024 , 05:48 PM

Analysts of IIFL Securities hosted JB Pharma at IIFL’s Investor Conference in Mumbai. JB’s 70-75% of incremental capital allocation is towards India and mgmt targets India and CMO businesses to contribute 75-80% of overall revenue vs currently at 65%. JB expects its India business to consistently outperform IPM by 300-400bps led by robust growth in Chronic segment, scaling up of acquired brands, and improving MR productivity. JB will also target 70-80% of the overall Ophthal market led by new launches and acquired Ophthal portofolio’s margins will improve to more than JB’s own domestic business margins once the perpetual license kicks-in. We believe with consistent volume-led outperformance in India business and mid-teens growth in CMO business, JB’s revenue/operating Ebitda will grow at 15/19% Cagr over the next 3 years. 

JB’s acquisition of Novartis’ Ophthal brands in India to catapult it among the top-4 players: 

Opthal market is growing at 13-14% and market is consolidated among the top-4 players with 35-40% MS, which is in-line with JB’s GTM approach of being present in limited segments but having market dominance. TAM for the 10 acquired brands is Rs8-10bn but JB can target 70-80% of the overall Ophthal market of Rs43bn led by new launches in the Ophthal market. JB is also targeting to cover 20K Ophthalmologist vs current coverage of 14-15K, led by the expansion of MRs. Post the in-licensing deal in 2027, the op. Ebitda margins of the acquired portfolio will be higher than the current op. Ebitda margins of JB’s domestic business led by in-sourcing. 

Consistently outperforming IPM growth, led by Chronic brands of Cilacar and Nicardia. Cilacar franchise has now become Rs6.5bn portfolio for JB with MS of 35-40%. Lobun and Oxalo have achieved annual revenue run-rate of Rs400-450mn pa together vs marginal sales at the time of acquisition. Its Sporlac and Razel acquired brands are also doing well while with increasing competition in Azamarda, JB’s target is to grow volumes. Mgmt targets to improve PCPM from Rs6.3 lakhs pm to >Rs7.5 lakhs pm over the next 12-18 months, even without Novartis Ophthal acquisition. 

Target India and CMO business to be 75-80% of overall revenue over the next 3-5 years, given these businesses are high margin and high return profile. On the India business front JB targets to outperform IPM by 300-400bps and will likely revert to mid-teens growth in CMO business led by addition of new geographies, new products and new clients.

Related Tags

  • JB Chemicals & Pharma
sidebar mobile

BLOGS AND PERSONAL FINANCE

Images
12 Apr 2024   |   01:37 PM
Images
12 Apr 2024   |   10:20 AM
Images
12 Apr 2024   |   10:16 AM
Read More

Most Read News

12 Apr 2024   |   08:25 PM
12 Apr 2024   |   08:14 PM
12 Apr 2024   |   08:13 PM
12 Apr 2024   |   08:13 PM
12 Apr 2024   |   08:08 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

closeIcon

Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp